Drug intelligence / Profile preview

dAd5GNE

Development stage: Phase 1
Lead developer: Weill Cornell Medicine
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

dAd5GNE is an anti-cocaine vaccine that works by preventing cocaine from reaching the brain. It consists of a cocaine analog (GNE) covalently linked to the capsid proteins of a disrupted serotype 5 adenovirus. The vaccine stimulates the immune system to produce antibodies that bind to cocaine molecules in the bloodstream, preventing them from crossing the blood-brain barrier and thus eliminating cocaine's effects on the brain. It was developed at Weill Cornell Medicine and NewYork-Presbyterian as a potential treatment for cocaine addiction.

Beyond the preview

Go deeper on dAd5GNE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dAd5GNE.

Explore the full profile